February 22, 2015 – Utrecht, The Netherlands
Crossbeta Biosciences today announced that PerkinElmer, Inc. has chosen Crossbeta’s stable oligomers for inclusion as reference standards in certain AlphaLISA® Research Immunoassay kits. The relationship has been initiated by joint activities on beta-amyloid 1-42-related applications with the option to expand to other protein oligomers.
So-called beta-amyloid oligomers play an important role in Alzheimer’s disease pathology. Alzheimer’s disease is the most common form of dementia, primarily affecting people over the age of 60. More than 26 million people across the globe are currently suffering from the condition, and this number is projected to rise to more than 100 million over the next four decades. In the absence of an effective treatment, Alzheimer’s disease is an illness with major social and economic impacts.
The new agreement between Crossbeta and PerkinElmer will contribute to insights into this devastating disease by providing highly disease-relevant and disease-specific research tools to the field. Crossbeta’s unique technology creates beta-amyloid oligomers with all the characteristics of patho-biologically relevant oligomers, but with the crucial difference that they are stable. The beta-amyloid oligomers serve as disease-relevant quantitative reference analytes for PerkinElmer’s AlphaLISA product range with improved sensitivity and specificity.
“We are very excited that Crossbeta’s oligomers have been selected as the reference standard by cutting-edge assay provider PerkinElmer,” said Guus Scheefhals, CEO of Crossbeta Biosciences. “It provides us with the unique opportunity of supporting the Alzheimer’s research community broadly in their endeavors to ultimately gain sufficient mechanistic and biologic understanding to ultimately develop better therapeutics for Alzheimer’s patients and those at risk.”
About Crossbeta Biosciences
Crossbeta Biosciences is a biotech company that owns a proprietary technology platform for efficient oligomer-based drug discovery, with applications in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and other misfolded protein diseases. Crossbeta’s technology enables the generation of well-defined stable, soluble and pathologically functional oligomers. These stable oligomers allow Crossbeta to develop robust assays for fast, efficient and de-risked compound library screening, for drug discovery. The platform can identify hit compounds that are able to reduce oligomer toxicity either by specifically interacting with the oligomers or by inhibiting particular receptors implicated in mediating oligomer toxicity. Crossbeta has demonstrated the unique capabilities of its technology platform with beta-amyloid oligomers, which play an important role in Alzheimer’s disease, and has successfully identified several compounds that neutralize their toxicity in vitro and in vivo. Crossbeta also provides services based on its proprietary technology to develop new oligomer targets and related screening assays.
About AlphaLISA Research Immunassay Kits
http://www.perkinelmer.com/Catalog/Category/ID/AlphaLISA%20Kits%20for%20Biomarkers%20and%20Cytokines
For further information:
Crossbeta Biosciences BV
Guus Scheefhals , CEO
Phone +31 30 253 2668
g.scheefhals@crossbeta.com
www.crossbeta.com
Help employers find you! Check out all the jobs and post your resume.
